Style Box ETF report for IWB
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Style Box ETF report for IWB
Canadian crypto miner Bitfarms (NASDAQ: $BITF) has announced plans to completely exit Bitcoin (CRYPTO: $BTC) as it ...
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SLS009, alternatively known as tambiciclib, is a […]
Fidelity Enhanced Large Cap Growth ETF (NYSEARCA:FELG) has slipped about 8% since the start of 2026, tracking closely with its benchmark as large-cap growth stocks broadly retreat. The fund gives investors exposure to the Russell 1000 Growth universe with a quantitative edge: Fidelity runs multifactor models to tilt toward companies with strong fundamentals and reasonable ... Fidelity’s ETF For Russell 1000 Large-Cap Growth
Assessing recent moves in SELLAS Life Sciences Group (SLS) SELLAS Life Sciences Group (SLS) has drawn attention after a recent run in its share price, with returns over the past 3 months and year that stand out against its mixed multi year track record. Over the past month the stock shows a gain, alongside a much stronger move in the past 3 months and a very large 1 year total return, while 5 year performance remains negative. That mix often prompts investors to revisit the story behind the...
A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have climbed 346% over the past year, yet the stock pulled back 13.4% in the past week to $5.04, with Q4 earnings due March 19. The reason Reddit is buzzing: ... SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths
Telesat (TSAT.TO) on Tuesday reported net loss which narrowed in the fourth quarter, despite a lower
UBS downgrade puts Infineon’s AI and China auto exposure in focus UBS cut its rating on Infineon Technologies (XTRA:IFX) to Neutral, highlighting what it sees as limited upside in the company’s AI-related business and forecasting 7% annual declines in China auto revenue in 2026 and 2027. See our latest analysis for Infineon Technologies. Infineon’s shares have been choppy recently, with a 1 month share price return of an 8.45% decline, even as the 90 day share price return of 9.77% and 1 year...
Seadrill delivers offshore drilling services worldwide, serving oil majors with a fleet of advanced rigs and a global client base.
Energy stocks fell Tuesday with the NYSE Energy Sector Index decreasing 0.8% and the State Street En
Although affordability challenges and land/labor costs pose risks, better operating leverage and marketing strategies are likely to drive homebuilders like TOL and GRBK.
Small caps are enjoying a renaissance in 2026. This ETF targets the space better than the others.
In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that its Phase 3 REGAL trial of Galinpepimut-S would continue unchanged after an Independent Data Monitoring Committee review. Taken together, these developments highlight both near-term clinical momentum around SLS009 and growing validation of Galinpepimut-S as a potential maintenance therapy in...
Executives at DeFi Development (NASDAQ:DFDV) used a monthly business recap and question-and-answer session to review February activity, discuss a reduction in near-term guidance tied to market conditions, and outline how a recent investment in a new stablecoin protocol could support future fundraisi
SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for Galinpepimut S. See our latest analysis for SELLAS Life Sciences Group. The recent clinical updates appear to be reflected in momentum, with a 44.8% 1 month share price return, a 217.8% 3 month share price return and a very large 1 year total shareholder return, although the 5 year total shareholder...
It was the rise of the rank and file for the last few months but with their slips, is it time for more cash?
US equity indexes fell on Friday amid weaker-than-expected February jobs data and higher inflation f
Richtech Robotics (NasdaqCM:RR) is facing multiple securities class action lawsuits over allegations that it misrepresented the nature of its relationship with Microsoft. Microsoft has reportedly said the engagement is limited to a standard customer program, not a broader commercial partnership. Law firms are seeking shareholders to act as lead plaintiffs, with regulatory attention increasing as key filing deadlines approach. For investors watching Richtech Robotics at a share price of...
The Dow Jones index fell and other indexes were mixed after President Trump spoke on Iran. A Warren Buffett stock dived but Palantir popped. Oil and defense stocks rose.
Rackspace Technology (NASDAQ:RXT) just reported its fourth-quarter results, showcasing signs of business improvement amid a challenging market. Revenue stabilized with only a slight decline, losses narrowed significantly, and key metrics beat analyst expectations. This comes on the heels of its recent partnership with Palantir Technologies (NASDAQ:PLTR), aimed at accelerating AI deployments. Yet, despite these positives, ... Rackspace Tumbles as Business Improves, but Is It a Buy Yet?
Asian equities traded in the US as American depositary receipts were sharply lower Friday morning, d
Not one, but two factors are leading a sell-off.
Palo Alto Networks shares slumped Wednesday after the cybersecurity software firm lowered its profit forecast for the year.
Company lowers full-year and Q3 adjusted EPS guidance while projecting revenue above Wall Street estimates.
Berkshire Hathaway late Tuesday disclosed a new position in the New York Times valued at about $350 million. Warren Buffett's Berkshire reduced positions in Apple, BofA and Amazon. Late Tuesday, New York Times shares rose 3% to a new high as Berkshire's stake became public.
Quantum Stocks Tank as Investors Pivot to Value; QUBT Defies Trend
Turbo Energy (TURB) announced the completion of a restructuring of its bank financing aimed at strengthening its financial position and aligning liquidity with the Company’s medium- and long-term business plan. As part of this process, Turbo Energy reached agreements with Bankinter, CaixaBank and BBVA, three of Spain’s leading financial institutions, enabling the conversion of existing bank facilities into long-term financing structures totaling approximately EUR 4.87M. This reorganization stren
One crypto observer suspects a fund holding Bitcoin call options got wiped out, triggering a broader crash.
SanDisk (SNDK) stock just got one of the most aggressive votes of confidence on Wall Street. Bernstein SocGen Group analyst Mark C. Newman just dropped a jaw-dropping new price target of $1,000 on the memory chip players' stock while keeping an outperform rating. The new target represents a 72.4% ...
Upexi (NASDAQ: UPXI) has terminated its asset management agreement with crypto research and trading firm GSR Strategies. According to a Form 8-K filing with the U.S. Securities and Exchange Commission, the termination became effective on Dec. 26, 2025, following months of disputes ...